Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

Blood

Volumn 119, Issue 18, 2012, Pages 4129-4132

  Kasamon, Yvette L ^a   Jacene, Heather A ^a   Gocke, Christopher D ^a   Swinnen, Lode J ^a   Gladstone, Douglas E ^a   Perkins, Brandy ^a   Link, Brian K ^b   Popplewell, Leslie L ^c   Habermann, Thomas M ^d   Herman, Joseph M ^a   Matsui, William H ^a   Jones, Richard J ^a   Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; DACARBAZINE; DOXORUBICIN; RITUXIMAB; VINBLASTINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLASSICAL HODGKIN LYMPHOMA; COPY NUMBER VARIATION; CORRELATION ANALYSIS; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; INFECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PRIORITY JOURNAL; REED STERNBERG CELL; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME;

EID: 84860741107     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-402792     Document Type: Article

References (24)

1. Younes A, McLaughlin P, GoyA, et al. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin's disease: A novel combination program targeting the cancer cells and the microenvironment [abstract]. Blood (ASH Annual Meeting Abstracts). 2003;102(11):Abstract 83.
2. Younes A, Romaguera J, Hagemeister F, et al.Apilot study of rituximab in patients with recurrent, classical Hodgkin disease. Cancer. 2003;98(2):310-314. (Pubitemid 36828455)
3. Newcom SR, Kadin ME, Phillips C. L-428 Reed-Sternberg cells and mononuclear Hodgkin's cells arise from a single cloned mononuclear cell. Int J Cell Cloning. 1988;6(6):417-431.
4. Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classical Hodgkin lymphoma. Blood. 2009;113(23):5920-5926.
5. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
6. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824-1833.
7. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood. 2000;96(13): 4055-4063.
8. Longo DL, Duffey PL, DeVita VT Jr,Wesley MN, Hubbard SM, Young RC. The calculation of actual or received dose intensity: A comparison of published methods. J Clin Oncol. 1991;9(11):2042-2051.
9. National Cancer Institute Common Toxicity Criteria, version 3.0. http://ctep.cancer.gov/protocol-Development/electronic-applications/docs/ ctcaev3.pdf. Accessed February 9, 2012.
10. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: Systematic review and meta-analysis. BMC Med. 2011;9:36.
11. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: Full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007; 18(2):376-380. (Pubitemid 46323108)
12. Younes A, McLaughlin P, Fayad LE, et al. Six weekly doses of rituximab plus ABVD for newly diagnosed patients with classical Hodgkin lymphoma: Depletion of reactive B-cells from the microenvironment by rituximab [abstract]. Blood (ASH Annual Meeting Abstracts). 2005;106(11): Abstract 1499.
13. Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008;112(4):831-836. (Pubitemid 351240577)
14. Kasamon YL, Jones RJ, Levitsky HI, et al. Highdose cyclophosphamide (Cy), rituximab, and a cancer vaccine for relapsed classical Hodgkin's lymphoma (cHL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 3954.
15. HD18 for advanced stages in Hodgkin's lymphoma. http://www. clinicaltrials.gov/ct2/show/NCT00515554. Accessed February 9, 2012.
16. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL) (HD0607) (multicenter clinical study with early treatment intensification in patients with high-risk Hodgkin lymphoma, identified as FDGPET scan positive after 2 conventional ABVD courses). http://www. clinicaltrials.gov/ct2/show/NCT00795613. Accessed February 9, 2012.
17. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009;27(32):5390-5396.
18. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805-811.
19. Younes A, Connors JM, Park SI, Hunder NNH, Ansell SM. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 155.
20. Ghiaur G, Gerber J, Jones RJ. Concise review: Cancer stem cells and minimal residual disease. Stem Cells. 2012;30(1):89-93.
21. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010;363(11): 1025-1037.
22. Gerber JM, Smith BD, Ngwang B, et al. A clinically relevant population of leukemic CD34 CD38 cells in acute myeloid leukemia Blood. 2012;119(15):3571- 3577.
23. Hohaus S, Santangelo R, Giachelia M, et al. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res. 2011;17(9):2885-2892.
24. Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res. 2006;12(2):460-464. (Pubitemid 43166136)